Acumen Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABOS Nasdaq 2834 acumenpharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acumen Pharmaceuticals, Inc.

Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Jan 27th, 2026 7:08 pm
Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Jan 26th, 2026 3:06 am
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - Jan 25th, 2026 4:05 am
January 2026's Rising Stars: Top Penny Stocks To Watch - Jan 19th, 2026 11:05 am
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Dec 2nd, 2025 6:00 am
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Nov 28th, 2025 11:05 am
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Nov 18th, 2025 6:00 am
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease - Nov 17th, 2025 6:00 am
Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Nov 12th, 2025 2:01 pm
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 12th, 2025 5:00 am
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors - Nov 10th, 2025 6:00 am
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 - Nov 5th, 2025 2:00 pm
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference - Nov 4th, 2025 2:00 pm
Uncovering Opportunities: Beauty Health Among 3 Promising Penny Stocks - Oct 29th, 2025 6:05 am
Promising Penny Stocks To Watch In September 2025 - Sep 30th, 2025 6:05 am
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - Aug 26th, 2025 2:00 pm
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - Aug 12th, 2025 5:00 am
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - Aug 5th, 2025 2:00 pm
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025 - Jul 28th, 2025 6:00 am
Acumen and JCR partner on brain delivery therapy for Alzheimer’s - Jul 16th, 2025 3:04 am